IRW

IRW is an orally active tripeptide produced from egg white with angiotensin converting enzyme (ACE) inhibitory properties. IRW can prevent high-fat diet (HFD) -induced Non-alcoholic fatty liver disease (NAFLD) by modulating hepatic lipid metabolism and increasing mitochondrial content. IRW decreases hepatic triglyceride content and lipid droplet size. IRW increases the hepatic mitochondrial complexes and citrate synthase activity, phosphorylation of 5’-AMP-activated protein kinase and microsomal triglyceride transfer protein abundance. IRW increases phosphorylated acetyl CoA carboxylase and mitochondrial complexes, IRW can be used for the research of inflammation[1].

159718-10-2

12352209

Acetyl-CoA Carboxylase; Angiotensin-converting Enzyme (ACE) ; Mitochondrial Metabolism

Metabolic Enzyme/Protease

Inflammation/Immunology

O=C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O)=O)[C@H]([C@@H](C)CC)N

C23H35N7O4

473.57

[1]Stepheny C. et al. IRW improves diet-induced non-alcoholic fatty liver disease by reducing steatosis associated with increased capacity for oxidative phosphorylation, Journal of Functional Foods, Volume 112, 2024, 105976, ISSN 1756-4646

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11358/

Peptides

No Development Reported